We are on a global mission
to engineer high-fidelity vaccines that protect humankind from the consequences of bacterial diseases.
Exclusive license to XpressCF™, an industrialized cell-free protein synthesis platform, for the vaccine field allowing: (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.
Assemblage of preeminent vaccinologists, vaccine developers & biotech company-builders joined together to harness the platform to create positive synergies to optimize development.
Endeavoring to deliver potentially superior and novel vaccines, beginning with its lead program: A broad-spectrum pneumococcal conjugate vaccine.
Backed by a world-class syndicate of private equity, venture capital, institutional & corporate venture investors.